Royal Bank of Canada Lowers Perspective Therapeutics (NYSE:CATX) Price Target to $16.00

Perspective Therapeutics (NYSE:CATX) had its target price reduced by Royal Bank of Canada from $25.00 to $16.00 in a research note issued to investors on Monday morning,Benzinga reports. Royal Bank of Canada currently has an outperform rating on the stock.

CATX has been the subject of several other research reports. Oppenheimer cut their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd. UBS Group began coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective for the company. Bank of America lowered shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $24.00 to $5.00 in a report on Monday. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Finally, Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They set a “buy” rating and a $21.00 price objective for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Stock Down 6.4 %

CATX opened at $4.12 on Monday. Perspective Therapeutics has a 12 month low of $2.28 and a 12 month high of $19.05. The business has a 50 day simple moving average of $10.96.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, hitting analysts’ consensus estimates of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, equities analysts expect that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Insider Buying and Selling

In other Perspective Therapeutics news, CFO Jonathan Robert Hunt acquired 12,829 shares of the stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the acquisition, the chief financial officer now owns 48,800 shares in the company, valued at $186,416. The trade was a 35.66 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Johan M. Spoor acquired 14,500 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $3.78 per share, with a total value of $54,810.00. Following the purchase, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 33,595 shares of company stock worth $126,625. Corporate insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. WealthPlan Investment Management LLC purchased a new position in shares of Perspective Therapeutics in the third quarter worth about $4,530,000. Hills Bank & Trust Co purchased a new position in Perspective Therapeutics in the 3rd quarter worth approximately $13,722,000. Nicholson Wealth Management Group LLC bought a new stake in Perspective Therapeutics in the third quarter valued at approximately $21,390,000. WealthPLAN Partners LLC purchased a new stake in shares of Perspective Therapeutics during the second quarter valued at approximately $1,695,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after purchasing an additional 93,548 shares during the last quarter. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.